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Summary 
 
Context: Optimisation of hydrocortisone replacement therapy is important to prevent under- and over 
dosing. Hydrocortisone pharmacokinetics is complex as circulating cortisol is protein bound mainly to 
corticosteroid-binding globulin (CBG) that has a circadian rhythm. 
Objective: A detailed analysis of the CBG circadian rhythm and its impact on cortisol exposure after 
hydrocortisone administration. 
Design and Methods: CBG was measured over 24 h in 14 healthy individuals and, employing a 
modelling and simulation approach using a semi-mechanistic hydrocortisone pharmacokinetic model, 
we evaluated the impact on cortisol exposure (area under concentration-time curve and maximum 
concentration of total cortisol) of hydrocortisone administration at different clock times and of the 
changing CBG concentrations.  
Results: The circadian rhythm of CBG was well described with two cosine terms added to the 
baseline of CBG: baseline CBG was 21.8 µg/mL and inter-individual variability 11.9%; the amplitude 
for the 24 h and 12 h cosine functions were relatively small (24 h: 5.53%, 12 h: 2.87%) and highest 
and lowest CBG were measured at 18:00 and 02:00, respectively. In simulations, the lowest cortisol 
exposure was observed after administration of hydrocortisone at 23:00-02:00, whereas the highest was 
observed at 15:00-18:00. The differences between the highest and lowest exposure were minor 
(12.2%), also rHJDUGLQJWKHIUHHFRUWLVROFRQFHQWUDWLRQDQGIUHHIUDFWLRQ.  
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Conclusions: CBG has a circadian rhythm but the difference in cortisol exposure is 12.2% between 
times of highest and lowest CBG concentrations; therefore hydrocortisone dose adjustment based on 
time of dosing to adjust for the CBG concentrations is unlikely to be of clinical benefit.  
 
ClinicalTrials.gov registration number: NCT01960530 
 
Key words: Hydrocortisone, Transcortin, Pharmacokinetics, Circadian Rhythm 
 
Introduction 
Oral hydrocortisone is the first-line glucocorticoid replacement therapy in patients suffering from 
adrenal insufficiency; recommended dosing in adults is 15-25 mg divided into two to three doses and 
in children 8 mg/m2 into three-four doses per day(1). Replacement therapy aims to mimic the 
endogenous circadian rhythm of cortisol, which is challenging due to the relatively short half-life of 
hydrocortisone (1.5 h)(2). Hydrocortisone, therefore, needs to be administered several times a day to 
maintain adequate cortisol concentrations throughout the day. To determine an optimal dosing 
regimen it is important to understand the factors that influence hydrocortisone pharmacokinetics.  
The absorption of hydrocortisone is fast and the maximum cortisol concentrations (Cmax) are observed 
1-1.4 h post-dose for 10-30 mg(2, 3) with approximately complete oral bioavailability(4). Absorption 
is delayed by food intake(5), and at higher doses(3). The area under the cortisol concentration-time 
curve (AUC) and Cmax of hydrocortisone are dose-dependent after intravenous and oral administration, 
resulting in a less than proportional increase in exposure in relation to the dose(3, 6). This nonlinearity 
is partly related to the saturable binding of cortisol to the low capacity protein corticosteroid-binding 
globulin (CBG): if total cortisol concentrations approach maximum binding capacity of CBG (Bmax ~ 
500 nmol/L)(7, 8), there is an increase in unbound cortisol concentration (Cu). Since only unbound 
cortisol is distributed and eliminated, an increased unbound fraction leads to increased total cortisol 
clearance (CL) and volume of distribution (V). Rapid and distinct changes in CBG may therefore result 
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in changes in Cu, CL, V and, thereby, potentially the exposure (Cmax, AUC) of hydrocortisone. Cortisol 
is also bound to albumin with a low affinity but high capacity. Rapid changes in albumin are therefore 
of less importance for cortisol pharmacokinetics. 
CBG has a circadian rhythm and it has been hypothesised that this could impact hydrocortisone 
exposure depending on whether the dose is administered in the morning or in the evening(9, 10). A 
recent study based on CBG measurements during daytime (08:00-19:00) did not identify a circadian 
rhythm of CBG, probably since CBG concentrations were not assessed during the night time period. 
The authors therefore concluded that the potential impact of circadian CBG on cortisol exposure was 
not a concern(10). Other studies have identified a circadian rhythm of CBG, but did not aim to 
evaluate its potential impact on hydrocortisone exposure(11, 12). To evaluate whether hydrocortisone 
dosing should be adapted according to clock time, we used CBG concentrations over 24 h to develop a 
model describing the time course of CBG. The established CBG model was linked to a semi-
mechanistic pharmacokinetic model for hydrocortisone to assess the impact on cortisol exposure (AUC 
and Cmax of total cortisol) after dosing hydrocortisone at different clock times and of changing CBG 
concentrations. 
Materials and Methods 
CBG measurements 
A total number of 350 CBG concentrations from a previously published study (ClinicalTrials.gov 
identifier: NCT01960530(12, 13)) with healthy volunteers were used for this analysis. The study was 
approved by the South East Wales Research Ethics committee, and performed according to local and 
international guidelines (ICH guideline for good clinical practice(14) and the Declaration of 
Helsinki(15)). Healthy volunteers in the age range of 18-60 years old with BMI between 21-28 kg/m2, 
without known cardiac, liver or renal disease, were included in the study after giving written consent. 
Individuals working night shift, smoking, using regular medication or with respiratory, cardiovascular, 
metabolic, central nervous system or gastrointestinal tract dysfunction were excluded. 14 individuals 
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in the age of median (range) 28.5 years (22-60) with body weight of 82.9 kg (63.6-103) were included 
in the study, from whom CBG concentrations measured over 24 h (from 15:00 on day one to 15:00 on 
day two) in absence of treatment, were used for the current analysis. Participants slept between 23:00 
to 06:00 with the lights out, received standardised meals at 13:00, 19:00 and 08:00, and were asked not 
to eat or drink 30 min before plasma sampling. CBG was sampled, diluted and quantified using an 
ELISA (Biovendor, Brno, Czech Republic) with a lower limit of quantification of 3.13 ng/mL and 
intra- and inter-assay variability <3% coefficient of variation (CV) and <8% CV, respectively(16). 
None of the CBG concentrations were below the lower limit of quantification. 
Circadian CBG model 
CBG concentrations from the study were analysed using a population approach in NONMEM 7.3(17). 
To best capture circadian processes, cosinor analysis was applied, which includes addition of one or 
several cosine functions(18): In this study, 1-3 cosine functions were added to describe the circadian 
rhythm of the CBG concentrations. Equations for two cosine functions with a periodicity of 24 h and 
12 h (CIRC24, CIRC12) are exemplified in Eq. 1-2, in which the amplitude (AMP24 and AMP12) and 
the time shift (shift24 and shift12) of the cosine functions are estimated. The respective circadian 
functions were sequentially added to the CBG baseline (CBGbaseline) in a proportional manner (Eq. 3). 
Variability between individuals was quantified using an exponential model, whereas a proportional 
model was used to consider variability within individuals (residual variability). Patient characteristics, 
such as body weight, height and age, explaining variability in the circadian CBG model were assessed. 
Visual predictive checks (VPC) were performed to assess how well the established model could 
predict the observed data: 1000 new datasets were simulated from the final model in NONMEM, from 
which the 5th, 50th and 95th percentiles of the CBG concentrations were extracted and compared 
graphically with the corresponding percentiles from the measured CBG concentrations in R (VPC 
package(19))  
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ܥܫܴܥଶସ ൌ ܣܯ ଶܲସ  ? ቀଶ ?గ ?ሺ௧௜௠௘ି௦௛௜௙௧మరሻଶସ ቁ   (Eq. 1) 
ܥܫܴܥଵଶ ൌ ܣܯ ଵܲଶ  ? ቀଶ ?గ ?ሺ௧௜௠௘ି௦௛௜௙௧భమሻଵଶ ቁ   (Eq. 2) ܥܤܩ ൌ ܥܤܩ௕௔௦௘௟௜௡௘  ?ሺ ? ൅ ܥܫܴܥଶସ ൅ ܥܫܴܥଵଶሻ   (Eq. 3) 
 
Simulations 
By using a modelling and simulation approach, we aimed to systematically evaluate the impact on 
cortisol exposure (AUC and Cmax of total cortisol) of changing CBG concentrations. In order to do so, 
the predicted CBG concentrations based on the above described CBG model was linked to a 
previously published semi-mechanistic pharmacokinetic (PK) model for hydrocortisone(13) (using a 
novel paediatric hydrocortisone formulation with taste masking). The PK model consisted of a two-
compartment disposition model with saturable absorption (Michaelis-Menten absorption) and a plasma 
protein binding model. The binding model considered both the nonlinear binding to CBG ± predicted 
by the circadian model ± and linear binding to albumin or erythrocytes. More details regarding the 
semi-mechanistic PK model for hydrocortisone can be found in Melin et al(13).  
The impact of changing CBG on simulated cortisol exposure was evaluated in a structured trial setting 
(scenario 1) and in a clinical use setting (scenario 2) for a typical patient (body weight was fixed to 70 
kg). 
 
Scenario 1: Impact of circadian CBG concentrations on cortisol exposure after single HC dose 
administration at different clock times (structured trial setting) 
The simulations were done in a stepwise manner: first the established circadian CBG model was used 
to simulate individual CBG concentration-time profiles over 24 h in a virtual patient population 
(n=100), allowing for variability in CBG concentrations between individuals. In the second step, 
cortisol exposure (AUC, Cmax) in the virtual population was simulated (allowing for variability in 
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cortisol PK parameters between individuals) after administration of single hydrocortisone doses (0.5, 
2, 5, 10 or 20 mg) at every hour of the day in 120 different scenarios (= 5 doses at 24 different 
administration times) to assess impact of dosing hydrocortisone at different clock times. The lowest 
and highest AUC (AUClow, AUChigh) and Cmax (Cmax,low, Cmax,high) of the individual cortisol PK profiles 
for every dose level and every dosing time were identified and compared according to Eq. 4 and 5, to 
derive the % increase from the lowest to highest exposure (% difference AUC and % difference Cmax). 
  ?݂݂݀݅݁ݎ݁݊ܿ݁ܣܷܥ ൌ  ? ? ?  ?ܣܷܥ௛௜௚௛ െ ܣܷܥ௟௢௪ܣܷܥ௟௢௪  (Eq. 4) 
 
 ?݂݂݀݅݁ݎ݁݊ܿ݁ܥ௠௔௫ ൌ  ? ? ? ?ܥ௠௔௫ǡ௛௜௚௛ െ ܥ௠௔௫ǡ௟௢௪ܥ௠௔௫ǡ௟௢௪  (Eq. 5) 
Scenario 2: Impact of circadian CBG concentrations on cortisol exposure after a recommended 
dosing regimen (clinical use setting) 
In scenario 2, cortisol concentration time-profiles were simulated using the established semi-
mechanistic PK model(13) assuming either circadian (N=100) or constant (N=100) CBG profiles, 
respectively. AUC from dosing to 8 h post-dose (AUC0-8h) and Cmax for cortisol were derived in the 
population with circadian (AUCcirc, Cmax,circ) and constant (AUCconst, Cmax,const) CBG concentrations 
assuming a recommended thrice daily dosing (10 mg at 06:00, 5 mg at 14:00 and 5 mg at 22:00) for 
adults(1). The % difference in AUC and Cmax by assuming circadian instead of constant CBG 
concentrations (% difference AUCcirc and % difference Cmax,circ) were derived according to Eq. 6 and 
Eq. 7. 
 
 ?݂݂݀݅݁ݎ݁݊ܿ݁ܣܷܥ௖௜௥௖ ൌ  ? ? ? ?ܣܷܥ௖௜௥௖ െ ܣܷܥ௖௢௡௦௧ܣܷܥ௖௢௡௦௧  (Eq. 6) 
 
 ?݂݂݀݅݁ݎ݁݊ܿ݁ܥ௠௔௫ǡ௖௜௥௖ ൌ  ? ? ? ?ܥ௠௔௫ǡ௖௜௥௖ െ ܥ௠௔௫ǡ௖௢௡௦௧ܥ௠௔௫ǡ௖௢௡௦௧  (Eq. 7) 
The simulations were done using NONMEM 7.3 (17), and the graphical evaluation and comparisons 
were done in R(20) for both scenarios.  
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Impact on free cortisol 
Since only total cortisol concentrations were considered in the current work so far, the 
pharmacokinetic model(13) was used to predict the free, i.e. unbound, cortisol concentration and free 
cortisol fraction for total cortisol concentrations ranging to the upper confidence level for Cmax after 
administration of 20 mg hydrocortisone (~900 nmol/L) for the minimum (median) and maximum 
(median) CBG concentrations observed over 24 h in the current population.  
Results  
Circadian CBG concentrations 
CBG concentrations obtained over the 24 h showed a clear circadian rhythm (Fig. 1, left). The 
maximum CBG concentration (CmaxCBG, median (range)) was 24.3 (20.0-29.5) µg/mL, representing a 
32.0% difference between the lowest and the highest CmaxCBG. The minimum CBG concentration 
(CminCBG) was 20.4 (15.9-23.5) µg/mL, with a difference comparable to CmaxCBG (32.2%). The relative 
change in CBG concentrations during 24 h (CmaxCBG/CminCBG) was 23.0% (16.4-38.8%), indicating that 
the variability within an individual is approximately equal to the variability between individuals. The 
time of CmaxCBG (tmaxCBG) and CminCBG (tminCBG) were (median (interquartile range)) 18:00 (with a smaller 
range of 18:00-19:00) and 03:30 (with a large range of 03:00-08:45), respectively. 
Circadian CBG model 
The circadian rhythm of CBG was well described with two cosine terms added to the baseline of 
CBG: The estimated baseline for CBG was 21.8 µg/mL and the associated interindividual variability 
was 11.9% CV (Table 1); the amplitude for the 24 and 12 h cosine functions were relatively small (24 
h: 5.53%, 12 h: 2.87%). The predicted CmaxCBG (18:00) and CminCBG (02:00) were in well agreement 
with the observed values. As seen in the VPC, comparing the percentiles of the observed data (black) 
and the simulated data (n=1000) using the final circadian CBG model (grey), the model could well 
predict the observed concentrations (Fig. 1, right). Addition of any covariates, such as height or body 
weight, to explain the variability in baseline was not supported by the data. 
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Impact on cortisol exposure  
The impact of changing CBG on simulated cortisol exposure was assessed in a structured trial setting 
(scenario 1) and in a clinical use setting (scenario 2) as follows. 
 
Scenario 1: Impact of circadian CBG concentrations on cortisol exposure after single HC dose 
administration at different clock times (structured trial setting) 
In scenario 1, the impact of dosing time of HC across 24 h of the day on AUC and Cmax for cortisol 
was simulated across all 5 doses (0.5-20 mg). The lowest and highest median AUC (AUChigh, AUClow) 
and median Cmax (Cmax,low, Cmax,high) for each different simulated dose levels are summarised in Table 2, 
and revealed that the maximum difference in AUC
 
(% difference AUC) was relatively small (9.48%-
12.2%), with the largest difference observed for the lower doses. The % difference Cmax ranged from 
4.20% to 9.01%. As seen in Fig. 2 (upper panels), the lowest cortisol exposure (AUClow) was observed 
for doses administered between 23:00-01:00, whereas AUChigh was observed for doses administered in 
the afternoon (15:00-16:00). The lowest and highest Cmax was observed for doses administered 01:00-
02:00 and 17:00-18:00, respectively. These times were slightly delayed compared to times for lowest 
and highest AUC.  
 
Scenario 2: Impact of circadian CBG concentrations on cortisol exposure after a recommended 
dosing regimen (clinical use setting) 
In scenario 2, the impact of assuming circadian or constant CBG concentrations on cortisol exposure 
(AUC0-8h, Cmax) in the clinical setting was simulated using the semi-mechanistic PK model for 
hydrocortisone with the constant(13) or circadian CBG model. As seen in Fig. 2 (lower panels), the 
simulated AUC0-8h was slightly lower when assuming circadian CBG profiles (light grey, AUCcirc) 
compared to constant CBG profiles (dark gray, AUCconst) for the doses in the morning (% difference 
AUCcirc: -8.29%) and evening (% difference AUCcirc: -10.4%); the % difference AUCcirc for the 
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afternoon dose was low (-2.79%). The impact of considering the circadian rhythm of CBG was small 
for Cmax for all doses, for which % difference Cmax,circ were ranging from -4.57% to -7.31% (Table 2). 
 
Impact on free cortisol  
The predicted free cortisol concentration and free fraction of cortisol for a large range of total cortisol 
concentrations are presented in Fig. 3. The free cortisol concentrations for the minimum (in black) and 
maximum (in grey) CBG were 105 and 92.6 nmol/L respectively for 900 nmol/L (Fig. 3, left), 
corresponding to the upper confidence level of total cortisol after administration of 20 mg 
hydrocortisone. The largest difference in free cortisol fraction for cortisol was observed for the higher 
concentrations, for which the impact of free cortisol fraction was minor (11.7% vs 10.3%, Fig 3, 
right), respectively. 
Discussion 
Therapy optimisation of hydrocortisone remains challenging due to complex pharmacokinetics and it 
has been suggested that cortisol pharmacokinetics is not constant during 24 h (chrono-
pharmacokinetics), due to the circadian rhythm of CBG(9). We have undertaken a detailed analysis 
employing a modelling and simulation approach to evaluate the impact of circadian CBG on cortisol 
exposure (AUC and Cmax of total cortisol) after administration of hydrocortisone. The results show that 
although there is a circadian rhythm in CBG, the amplitude is relatively small and has little impact on 
cortisol exposure. It is therefore likely to be of little clinical relevance with respect to hydrocortisone 
dosing.  
Previous studies have identified a circadian rhythm of CBG(11, 21), whereas other studies have failed 
to do so(10). In the present study, the hourly CBG measurements during a 24 h period showed a clear 
circadian rhythm. In the current analysis, the circadian rhythm of CBG over a full day was well 
described by adding two cosine functions to the CBG baseline model. The precision of the parameters 
quantifying the circadian behaviour was good and both CmaxCBG and CminCBG were well predicted by the 
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model. However, it should be noted that the observed CBG concentrations in our study were 
approximately constant during the daytime, which could explain why a constant CBG model was used 
to describe the data from 07:00-19:00(13) in the previous HC PK analysis. Since the CBG 
concentrations used in the current analysis were measured in healthy male volunteers, the impact of 
higher CBG concentrations in females compared to males(22) and in females on estrogen 
contraceptives (23, 24) or lower CBG concentrations in obese patients(22) could not be considered. 
However, higher CBG concentrations are expected to result in less fluctuation, and hence less impact 
on cortisol exposure than the scenario assessed in this analysis. Lower CBG concentrations may 
however result in larger fluctuations and more profound impact on cortisol exposure than observed in 
this analysis, which should be evaluated further in clinical studies.  
In order to evaluate the potential impact of circadian CBG on cortisol exposure after administration of 
hydrocortisone, a previously established semi-mechanistic PK model of cortisol was combined with 
the here presented, validated circadian CBG model. First the impact of dosing time of HC 
administration was evaluated looking at the changes on cortisol exposure (AUC and Cmax) when HC 
was administered at different hours. To do so, simulations were performed administering a single dose 
of a wide range of HC doses across the 24 possible hours of the day (structured trial setting). 
Secondly, the impact of considering the circadian CBG rhythm or not was compared for a clinically 
used dosing regimen (clinical setting). Even though CBG has a circadian rhythm, the prediction 
intervals for the lowest and highest simulated AUC and Cmax of cortisol in scenario 1 were largely 
overlapping for all hydrocortisone doses including the high ones with nonlinear PK. The differences 
between the lowest and highest median AUC and Cmax in the respective dose group were minor (% 
difference AUC: 9.48%-12.2%, % difference Cmax: 4.20%-9.01%). These results indicate that the 
circadian rhythm of the binding protein CBG does not translate into a major difference in the exposure 
of cortisol. This could be due to the relatively small difference (~23%) between the lowest and highest 
CBG concentrations, which also resulted in relatively small amplitudes in the circadian variation.  
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The maximum CBG concentrations were measured around 18:00-19:00. During this time, the unbound 
fraction of cortisol is expected to be the lowest. Since maximum cortisol concentrations are observed 
approximately 1 h post-dose, the highest Cmax for cortisol would be predicted for HC doses 
administered shortly before the observed time of maximum CBG concentration. This was in 
agreement with the Cmax,high of cortisol, which was observed for doses administered 17:00-18:00. The 
highest AUC of cortisol was observed for doses administered slightly earlier (15:00-16:00), probably 
due to the higher impact of clearance during the elimination phase which occurs later. The lowest Cmax 
and AUC were observed for doses administered at 01:00-02:00 and 23:00-01:00, respectively. These 
time ranges occurred shortly before the lowest CBG concentrations around 03:30, when the unbound 
fraction, is at its highest. 
Scenario 1 allowed us to systematically explore the impact of hydrocortisone dosing throughout the 
GD\KRZHYHU LW LVQRWUHIOHFWLQJWKH³UHDO´FOLQLFDOVFHQDULR*LYHQWKDW&%*FRQFHQWUDWLRQVUHPDLQ
fairly constant during daytime, we evaluated the impact of including the circadian rhythm of CBG 
using a real clinical setting, in which hydrocortisone was dosed according to a clinically relevant thrice 
daily dosing regimen. Median exposure assuming circadian CBG was in general (morning, evening 
dosing) slightly lower compared to assuming constant CBG. Assuming circadian instead of a constant 
CBG concentrations resulted in the largest difference in AUC for the morning and the evening dose (% 
difference AUCcirc: 9%-11%) probably since the circadian CBG concentrations were slightly lower 
than the constant CBG during these times. The interquartile ranges and 95% prediction intervals for 
AUC and Cmax were however overlapping as in scenario 1, indicating that the difference is not 
clinically relevant. 
Since our analysis was based on total cortisol concentrations, rather than the free, i.e. unbound, 
cortisol concentrations, we used the pharmacokinetic model to demonstrate the impact of changing 
CBG on the free cortisol concentrations and free cortisol fraction. As discussed in the introduction and 
seen in Fig. 3, free unbound cortisol rises with higher concentrations of cortisol and the proportion of 
free cortisol increases in respect of total cortisol as the cortisol concentration exceeds the binding 
capacity of CBG. At CBG concentrations corresponding to the minimum (median: 20.4 µg/mL) and 
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maximum (median: 24.3 µg/mL) CBG, the variation in the free fraction at higher concentrations was 
small (11.7% vs 10.3%), and of little clinical relevance. The slightly higher free fraction will also 
translate into a slightly higher clearance of high doses of hydrocortisone. As stated previously, cortisol 
is also bound to albumin, which also has a circadian rhythm (12). The circadian variation was however 
minor (median peak:through ratio: 1.09), and not likely to impact cortisol pharmacokinetics due to the 
low affinity but high capacity binding to cortisol. 
To evaluate the clinical relevance of the differences in exposure, one may hypothesise how a 
difference in AUC or Cmax may translate into difference in pharmacodynamic effect. Assuming that the 
pharmacodynamic effect mediated by cortisol upon binding to the glucocorticoid-receptor is linear, 
this may indicate a maximum of ~10% difference in effect depending on timing of dose. A 10% 
difference is relatively small compared to the variability in PK parameters (~25%-30%CV)(13) and 
variability associated with other sources. The impact of the circadian CBG rhythm on hydrocortisone 
exposure is, therefore, unlikely to be clinically relevant, and dose adjustments based on when the dose 
is administered are probably not required. 
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Tables 
Table 1. Parameter estimates for the circadian corticosteroid-binding globulin (CBG) model 
developed on CBG concentrations observed during 24 h. 
 
Typical 
parameter 
estimate 
95% CI 
Fixed-effects 
  
BaselineCBG [µg/mL] 21.8 20.3, 23.3 
Amp24 [%] 5.53 4.80, 6.20 
Shift24 [h] 1.77 1.33, 2.27 
Amp12 [%] 2.87 2.21, 3.42 
Shift12 [h] 15.7 15.4, 16.0 
Interindividual 
variability   
ȦBaselineCBG [CV%] 11.9 7.76, 14.0 
Residual variability 
  
ıprop [CV%] 3.90 3.46, 4.32 
 
95% confidence interval (95% CI), amplitude for 24 h cosine function (Amp24), time shift for 24 h 
cosine function (Shift24), amplitude for 12 h cosine function (Amp12), time shift for 12 h cosine 
function (Shift12), variance of log-normally distributed interindividual variability (Ȧ), variance or 
proportional residual variability (ıprop). 
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Table 2. Impact of circadian corticosteroid-binding globulin (CBG) concentrations on simulated 
hydrocortisone exposure (n=100). Scenario 1: After single oral administration of hydrocortisone 
(0.5-20 mg) every hour of the day. The lowest and highest simulated area under cortisol 
concentration curve (AUClow & AUChigh ) and maximum cortisol concentration (Cmax, low & Cmax, 
high). The percentage difference for AUC and Cmax. Scenario 2: Simulated AUC and Cmax 
assuming constant (AUCconst, Cmax,const) or circadian CBG (AUCcirc, Cmax,circ) after a three times 
daily dosing of hydrocortisone (10 mg at 06:00, 5 mg at 14:00 and 5 mg at 22:00). The difference 
in AUC and Cmax between groups with constant and circadian profile (% difference AUCcirc, % 
difference Cmax,circ). 
Scenario 1 
Dose 
AUClow
a
 AUChigh
a
 % difference 
AUC 
C
max, low
a
 C
max, high
a
 % difference 
C
max
 
0.5 mg 164 
(87.6, 311) 
183 
(97.8, 346) 
11.6 95.9 
(60.5, 156) 
100 
(62.8, 163) 
4.20 
2 mg 515 
(303, 890) 
577 
(341, 989) 
12.2 260 
(174, 373) 
279 
(185, 405) 
7.42 
5 mg 962 
(608, 1580) 
1070 
(678, 1730) 
11.3 412 
(288, 557) 
449 
(313, 602) 
9.01 
10 mg 1510 
(991, 2410) 
1650 
(1100, 2600) 
9.60 517 
(376, 684) 
561 
(409, 734) 
8.42 
20 mg 2390 
(1620, 3740) 
2620 
(1780, 3980)  
9.48 605 
(442, 818) 
652 
(479, 871) 
7.93 
Scenario 2  
Dose 
AUC
const
a
 AUC
circ
a
 % difference 
AUC
circ 
C
max, const
a
 C
max,
 
circ
a
 % difference 
C
max, circ 
Morning 
(10 mg) 
1660 
(1020, 2460) 
1530  
(992, 2210) 
-8.29 574 
(395, 721) 
532 
(395, 676) 
-7.31 
Afternoon 
(5 mg) 
1080 
(641, 1680) 
1050  
(654, 1590) 
-2.79 472 
(312, 602) 
451 
(321, 567) 
-4.57 
Evening 
(5 mg) 
1080 
(639, 1660) 
965 
(605.0, 1450) 
-10.4 471 
(311, 598) 
439 
(313, 555) 
-6.70 
 
aMedian (95% confidence interval) 
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Figure legends 
 
Figure 1 Left: Change in corticosteroid-binding globulin from baseline over time (left), during 
24 h (n=14). Right: Visual predictive check for the circadian corticosteroid-binding globulin 
model during 24 h (15:00 day 1-15:00 day 2). Lines correspond to the 5th, 50th and 95th percentile 
of observed (black) and simulated (n=1000, grey) data. The areas are the 95th confidence interval 
around the percentiles and the circles the observations. 
Figure 2 Impact on cortisol exposure: Simulation scenario 1 (top): Simulated area under cortisol 
concentration-time curve (AUC) and maximum cortisol concentration (Cmax) after single oral 
administration of hydrocortisone every hour during 24 h to 100 individuals with different 
circadian corticosteroid-binding globulin (CBG) profiles. The box corresponds to the 
interquartile range; the line in the box the median. 
Scenario 2 (bottom): Simulated AUC from dosing to 8 h post-dose (AUC0-8h) and Cmax after 
administration of hydrocortisone 10 mg in the morning (06:00), 5 mg in the afternoon (14:00) 
and 5 mg in the evening (22:00) for virtual patients with constant (dark gray, n=100) or 
circadian (light gray, n=100) CBG profiles, respectively. The box correspond to the interquartile 
range; the whiskers to the observations at most 1.5*interquartile range from the upper and 
lower quartiles; the line in the box to the median; the dots to outliers. 
Figure 3 Predicted free, i.e. unbound, cortisol concentration versus total cortisol concentration 
(left) and predicted free cortisol fraction versus total cortisol concentration (right) for the 
maximum corticosteroid-binding globulin (CBG, 24.3 µg/mL) and minimum CBG (20.4 µg/mL) 
concentration based on the pharmacokinetic model(13). 
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